Biomedical firm Novocure (NASDAQ: NVCR) has announced the U.S. Food and Drug Administration’s (FDA) acceptance for filing of its Premarket Approval (PMA) application. The PMA is focused on procuring authorization for the use of Tumor Treating Fields (TTFields) therapy jointly with standard systemic therapies to treat non-small cell lung cancer (NSCLC), after a patient has experienced progression post-platinum-based therapy implementation.
Novocure, headquartered in Root, Switzerland, is eagerly anticipating the FDA’s assessment of its futuristic TTFields therapy’s effectiveness. The proposed method supplements standard systemic treatments currently used against non-small cell lung cancer. The therapy is a novel anti-mitotic treatment which uses specially insulated electrodes applied to the skin’s surface to generate low-intensity, wave-like electric fields within the tumor. The specific frequencies interfere with the division of cancerous cells, potentially inhibiting tumor growth.
The filing signifies an important advance in the journey of TTFields therapy towards mainstream use. A favorable FDA decision is anticipated to boost Novocure’s market standing significantly. Particularly, it could hold promise for the substantial population of NSCLC patients that demonstrate disease progression following platinum-based therapies. NSCLC accounts for approximately 85% of all lung cancers, making advancements in this area of oncology crucial.
We are thrilled to announce the FDA has accepted our PMA application, said a spokesperson for Novocure. This is an encouraging step for those battling NSCLC as we continue to push the boundaries of cancer treatment.
The approval of TTFields therapy could potentially reorient the approach towards NSCLC treatment, offering patients alternatives that extend beyond conventional systemic therapies. As of now, the healthcare community and the patients alike are awaiting the FDA’s final decision.
Comments